Results of Duodenopancreatic Reoperations in Multiple Endocrine Neoplasia Type 1.
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
pubmed:
6
10
2018
medline:
27
6
2019
entrez:
6
10
2018
Statut:
ppublish
Résumé
To evaluate the outcome of duodenopancreatic reoperations in patients with multiple endocrine neoplasia type 1 (MEN1). MEN1 patients who underwent reoperations for duodenopancreatic neuroendocrine neoplasms (dpNENs) were retrieved from a prospective database and retrospectively analyzed. Twelve of 101 MEN1 patients underwent up to three reoperations, resulting in a total of 18 reoperations for dpNEN recurrence. Patients initially underwent either formal pancreatic resections (n = 7), enucleations (n = 3), or duodenotomy with lymphadenectomy for either NF-pNEN (seven patients), Zollinger-Ellison syndrome (ZES, three patients), organic hyperinsulinism (one patient) or VIPoma (one patient). Six patients had malignant dpNENs with lymph node (n = 5) and/or liver metastases (n = 2). The indication of reoperations was NF-pNEN (five patients), ZES (five patients), organic hyperinsulinism (one patient), and recurrent VIPoma (one patient). Median time to first reoperation was 67.5 (range 6-251) months. Five patients required a second duodenopancreatic reoperation for 60-384 months after initial surgery, and one patient underwent a third reoperation after 249 months. The rate of complications (Clavien-Dindo ≥3) was 28%. Four patients required completion pancreatectomy. Six patients developed pancreoprivic diabetes. After a median follow-up of 18 (6-34) years after initial surgery, ten of 12 patients are alive, one died of metastatic pancreatic VIPoma, and one died of metastatic thymic NEN. Reoperations are frequently necessary for dpNEN in MEN1 patients, but are not associated with an increased perioperative morbidity in specialized centers. Organ-sparing resections should be preferred as initial duodenopancreatic procedures to maintain pancreatic function and avoid completion pancreatectomy.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the outcome of duodenopancreatic reoperations in patients with multiple endocrine neoplasia type 1 (MEN1).
METHODS
METHODS
MEN1 patients who underwent reoperations for duodenopancreatic neuroendocrine neoplasms (dpNENs) were retrieved from a prospective database and retrospectively analyzed.
RESULTS
RESULTS
Twelve of 101 MEN1 patients underwent up to three reoperations, resulting in a total of 18 reoperations for dpNEN recurrence. Patients initially underwent either formal pancreatic resections (n = 7), enucleations (n = 3), or duodenotomy with lymphadenectomy for either NF-pNEN (seven patients), Zollinger-Ellison syndrome (ZES, three patients), organic hyperinsulinism (one patient) or VIPoma (one patient). Six patients had malignant dpNENs with lymph node (n = 5) and/or liver metastases (n = 2). The indication of reoperations was NF-pNEN (five patients), ZES (five patients), organic hyperinsulinism (one patient), and recurrent VIPoma (one patient). Median time to first reoperation was 67.5 (range 6-251) months. Five patients required a second duodenopancreatic reoperation for 60-384 months after initial surgery, and one patient underwent a third reoperation after 249 months. The rate of complications (Clavien-Dindo ≥3) was 28%. Four patients required completion pancreatectomy. Six patients developed pancreoprivic diabetes. After a median follow-up of 18 (6-34) years after initial surgery, ten of 12 patients are alive, one died of metastatic pancreatic VIPoma, and one died of metastatic thymic NEN.
CONCLUSION
CONCLUSIONS
Reoperations are frequently necessary for dpNEN in MEN1 patients, but are not associated with an increased perioperative morbidity in specialized centers. Organ-sparing resections should be preferred as initial duodenopancreatic procedures to maintain pancreatic function and avoid completion pancreatectomy.
Identifiants
pubmed: 30288555
doi: 10.1007/s00268-018-4809-1
pii: 10.1007/s00268-018-4809-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
552-558Références
J Clin Endocrinol Metab. 2001 Nov;86(11):5282-93
pubmed: 11701693
Langenbecks Arch Surg. 2002 Mar;386(8):558-69
pubmed: 11914931
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Surgery. 2004 Dec;136(6):1205-11
pubmed: 15657577
Surgery. 2005 Jul;138(1):8-13
pubmed: 16003309
Ann Surg. 2006 Feb;243(2):265-72
pubmed: 16432361
World J Surg. 2006 May;30(5):654-62; discussion 663-4
pubmed: 16680582
Am J Surg Pathol. 2006 May;30(5):560-74
pubmed: 16699310
Exp Clin Endocrinol Diabetes. 2006 Jul;114(7):361-5
pubmed: 16915538
J Clin Endocrinol Metab. 2009 Oct;94(10):3640-6
pubmed: 19622622
Surgery. 2009 Oct;146(4):801-6; discussion 807-8
pubmed: 19789041
World J Surg. 2010 Feb;34(2):249-55
pubmed: 19949948
Langenbecks Arch Surg. 2011 Dec;396(8):1187-96
pubmed: 21805182
Ann Surg. 2013 Feb;257(2):308-14
pubmed: 22580937
J Clin Endocrinol Metab. 2012 Sep;97(9):2990-3011
pubmed: 22723327
JOP. 2012 Jul 10;13(4):402-8
pubmed: 22797396
Medicine (Baltimore). 2013 May;92(3):135-81
pubmed: 23645327
Neuroendocrinology. 2013;98(4):290-8
pubmed: 24356648
J Clin Endocrinol Metab. 2014 Nov;99(11):E2387-91
pubmed: 25210877
Neuroendocrinology. 2016;103(6):779-86
pubmed: 26731608
Neuroendocrinology. 2016;103(2):153-71
pubmed: 26742109
J Gastroenterol. 2017 Jan;52(1):9-18
pubmed: 27539256
Ann Surg. 2018 Feb;267(2):352-356
pubmed: 27811505
World J Surg. 2017 Jun;41(6):1521-1527
pubmed: 28138732
Pancreas. 2017 May/Jun;46(5):589-594
pubmed: 28426491
Endocr Relat Cancer. 2017 Oct;24(10):T209-T225
pubmed: 28790162
Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):353-363
pubmed: 28823364
World J Surg. 2018 May;42(5):1440-1447
pubmed: 29075857